Hepatitis E: Update on Prevention and Control

Hepatitis E virus (HEV) is a common etiology of acute viral hepatitis worldwide. Recombinant HEV vaccines have been developed, but only one is commercially available and licensed in China since 2011. Epidemiological studies have identified genotype 3 as the major cause of chronic infection in immuno...

Full description

Saved in:
Bibliographic Details
Published inBioMed research international Vol. 2018; no. 2018; pp. 1 - 9
Main Authors Lewis-Ximenez, Lia Laura, Leal, Mariana, Mello, Vinicius da Motta de, Gardinali, Noemi Rovaris, Melgaço, Juliana Gil, Pinto, Marcelo Alves
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Publishing Corporation 01.01.2018
Hindawi
Hindawi Limited
Subjects
Chronic infection
Epidemiology
Etiology
Genomes
Genotype & phenotype
Genotypes
Hepatitis
Immunosuppressive agents
Infections
Prevention
Proteins
Public health
Review
Ribavirin
Transplants & implants
Vaccines
Viruses
Online AccessGet full text

Cover

More Information
Summary:Hepatitis E virus (HEV) is a common etiology of acute viral hepatitis worldwide. Recombinant HEV vaccines have been developed, but only one is commercially available and licensed in China since 2011. Epidemiological studies have identified genotype 3 as the major cause of chronic infection in immunocompromised individuals. Ribavirin has been shown to be effective as a monotherapy to induce HEV clearance in chronic patients who have undergone solid organ transplant (SOT) under immunosuppressive therapy. Efforts and improvements in prevention and control have been made to reduce the instances of acute and chronic hepatitis E in endemic and nonendemic countries. However, this review shows that further studies are required to demonstrate the importance of preventive vaccination and treatment worldwide, with emphasis on hepatitis E infection in the public health system.
Bibliography:Academic Editor: Antonio Rivero-Juarez
ISSN:2314-6133
2314-6141
DOI:10.1155/2018/5769201